Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis

Table 2 Significant differential peptide peaks between bone metastasis hepatocellular carcinoma group and bone metastasis-free hepatocellular carcinoma group

Serial number	m/z	PTTA (t)	P-W test	PAD_1	PAD_2	HCC groups (n = 38)	Bone metastasis HCC groups (n = 38)
1	1780.7	3.60 × 10-4	1.58 × 10-4	0.026	0.048	110.3	333.7
2	1866.5	8.48 × 10-5	2.80 × 10-4	0.136	0.500	750.1	1703.5
3	2131.6	6.30 × 10-2	2.99 × 10-4	0.031	0.001	42.3	129.8
4	2880.4	2.00 × 10-3	3.68 × 10-4	0.100	0.005	142.5	294.9
5	1532.4	7.30 × 10-2	6.32 × 10-4	0.001	0.001	70.8	138.1
6	2901.9	9.57 × 10-4	9.38 × 10-4	0.078	0.065	99.3	182.2
7	2489.8	7.70 × 10-2	2.00 × 10-3	0.208	0.001	31.1	70.5
8	3061.1	1.02 × 10-1	2.00 × 10-3	0.010	0.001	30.1	74.9
9	2234.3	9.00 × 10-3	3.00 × 10-3	0.118	0.003	91.1	171.5
10	2864.1	7.00 × 10-3	3.00 × 10-3	0.029	0.009	135.5	337.0

Serial numbers of the top ten peaks; m/z: Mass to charge ratio; PTTA (t): P value of t-test or ANOVA (analysis of variance); P-W test: P value of the Wilcoxon test; PAD_1: P value of the Anderson-darling normal test (HCC groups); PAD_2: P value of the Anderson-darling normality test (bone metastasis HCC group); HCC group (38): Average peak of the arithmetic means of 38 HCC samples; Bone metastasis HCC group (38): Average peak of the arithmetic means of 38 bone metastasis from HCC samples. HCC: Hepatocellular carcinoma.